Ketek: More safety warnings will affect sales
The antibiotic Ketek is likely to face more safety warnings. Sanofi-Aventis’ stock for the sales of Ketek will most likely be hurt in the United States and Europe. (New Ratings)
« November 2006 | Main | January 2007 »
December 13, 2006
December 12, 2006
FDA seeks outside review of Ketek antibiotic on December 14 and 15
The antibiotic Ketek, is under scrutiny amid reports of liver failure in a dozen patients. Ketek, approved in 2004, is also the subject of a Senate Finance Committee investigation because of the FDA's handling of the approval and of possibly faulty data.